Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The Pericapsular Nerve Group (PENG) block is a regional anesthesia technique primarily used for postoperative pain management in hip and knee surgeries. In the clinical trial context provided by Bursa City Hospital, the PENG block involves the ultrasound-guided administration of a local anesthetic, specifically 30 ml of 0.25% bupivacaine (Marcain), into the fascial plane between the psoas tendon and the superior pubic ramus. This technique targets the articular branches of the femoral, obturator, and accessory obturator nerves to provide effective analgesia while potentially sparing motor function. Bupivacaine, the active pharmaceutical agent, acts by blocking voltage-gated sodium channels, thereby inhibiting the initiation and conduction of pain signals from the surgical site.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Pericapsular Nerve Group block.